Skip to main content
Premium Trial:

Request an Annual Quote

Microbial DNA Specialist OpGen Pockets $23.6M in Series A VC Cash

NEW YORK (GenomeWeb News) — OpGen has received $23.6 million in Series A private-equity financing that it plans to use to “develop commercial instrumentation systems for the clinical microbiology marketplace.”   
 
OpGen, a Madison, Wisc.-based company specializing in analyzing microbial DNA, also said it is looking for a new chief executive.
 
The cash came from three new venture capital investors, including CHL Medical Partners, Highland Capital Partners, and Versant Ventures. Existing investor Mason Wells also contributed in the round.
 
OpGen said it has added to its board of directors one investor each from Highland and Versant. Ron Lennox from CHL will become chairman of OpGen’s board, the company said. Lennox will be joined on the board by Corey Mulloy and Bijan Salehizadeh from Highland, and Versant's Brian Atwood.

The Scan

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.

Survey Sees Genetic Literacy on the Rise, Though Further Education Needed

Survey participants appear to have higher genetic familiarity, knowledge, and skills compared to 2013, though 'room for improvement' remains, an AJHG paper finds.

Study Reveals Molecular, Clinical Features in Colorectal Cancer Cases Involving Multiple Primary Tumors

Researchers compare mismatch repair, microsatellite instability, and tumor mutation burden patterns in synchronous multiple- or single primary colorectal cancers.

FarGen Phase One Sequences Exomes of Nearly 500 From Faroe Islands

The analysis in the European Journal of Human Genetics finds few rare variants and limited geographic structure among Faroese individuals.